Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24856037
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24856037
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Trends+Endocrinol+Metab
2014 ; 25
(7
): 364-73
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
mTORC2 in the center of cancer metabolic reprogramming
#MMPMID24856037
Masui K
; Cavenee WK
; Mischel PS
Trends Endocrinol Metab
2014[Jul]; 25
(7
): 364-73
PMID24856037
show ga
Metabolic reprogramming is a central hallmark of cancer, enabling tumor cells to
obtain the macromolecular precursors and energy needed for rapid tumor growth.
Understanding how oncogenes coordinate altered signaling with metabolic
reprogramming and global transcription may yield new insights into tumor
pathogenesis, and provide a new landscape of promising drug targets, while
yielding important clues into mechanisms of resistance to the signal transduction
inhibitors currently in use. We review here the recently identified central
regulatory role for mechanistic target of rapamycin complex 2 (mTORC2), a
downstream effector of many cancer-causing mutations, in metabolic reprogramming
and cancer drug resistance. We consider the impact of mTORC2-related metabolism
on epigenetics and therapeutics, with a particular focus on the intractable
malignant brain tumor, glioblastoma multiforme (GBM).